Drugs / PRAX-562
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05818553 | Aug 2023 → Nov 2025 overdue | genetic developmental and epileptic encephalopathy | Praxis Precision Medicines | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07010471 | Jul 2025 → Dec 2026 expected | genetic developmental and epileptic encephalopathy | Praxis Precision Medicines | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRAX-562 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05818553 ↗ |
| Route | Oral | “administered orally or via gastrostomy tube (G-tube).” NCT05818553 ↗ |